These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 24525551)

  • 1. Baroreflex activation therapy in patients with pre-existing implantable cardioverter-defibrillator: compatible, complementary therapies.
    Madershahian N; Scherner M; Müller-Ehmsen J; Halbach M; Hickethier T; Velden R; Choi YH; Wippermann J; Wahlers T
    Europace; 2014 Jun; 16(6):861-5. PubMed ID: 24525551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical experience of combined HeartWare ventricular assist device and implantable cardioverter defibrillator therapy.
    Pecha S; Wilke I; Bernhardt A; Hakmi S; Yildirim Y; Steven D; Reichenspurner H; Willems S; Deuse T; Aydin A
    J Cardiovasc Electrophysiol; 2014 Oct; 25(10):1109-14. PubMed ID: 24862733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of a wireless implantable cardioverter defibrillator in a patient with a preexisting neurostimulator.
    Katwal AB; McCotter CJ
    Pacing Clin Electrophysiol; 2009 Jun; 32(6):822-4. PubMed ID: 19545350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual implantable electronic device therapy.
    Reif S; Steiner P; Hoffmann E
    Europace; 2014 Sep; 16(9):1321. PubMed ID: 25031232
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical experience and procedural outcomes associated with the DF4 implantable cardioverter defibrillator system: the SJ4 postapproval study.
    Cantillon DJ; Ha K; Styperek R; Jumrussirikul P; Mirro M; Wong W; Wilkoff BL
    Pacing Clin Electrophysiol; 2013 Jul; 36(7):855-62. PubMed ID: 23617316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ICD proarrhythmia as a consequence of an interaction with an algorithm to prevent atrial arrhythmias.
    Martínez-Sánchez J; García-Alberola A; Sánchez-Muñoz JJ; Peñafiel-Verdú P; Giner-Caro JA; Valdés-Chávarri M
    Pacing Clin Electrophysiol; 2009 Aug; 32(8):1096-8. PubMed ID: 19659632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical relevance of slow ventricular tachycardia in heart failure patients with primary prophylactic implantable cardioverter defibrillator indication.
    Lüsebrink U; Duncker D; Hess M; Heinrichs I; Gardiwal A; Oswald H; König T; Klein G
    Europace; 2013 Jun; 15(6):820-6. PubMed ID: 23325044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-determinable defibrillation threshold and inefficacy of implantable cardioverter/defibrillator shocks due to defective connections of the defibrillator lead terminals in the device header port.
    Maagh P; Trappe HJ; Meissner A
    Europace; 2007 Dec; 9(12):1161-2. PubMed ID: 17913694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical development of the automatic implantable defibrillator over 35 years: A success story].
    Steinbeck G
    Herzschrittmacherther Elektrophysiol; 2015 Jun; 26(2):70-4. PubMed ID: 25990264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial.
    Hoppe UC; Brandt MC; Wachter R; Beige J; Rump LC; Kroon AA; Cates AW; Lovett EG; Haller H
    J Am Soc Hypertens; 2012; 6(4):270-6. PubMed ID: 22694986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous use of implantable cardioverter-defibrillators and left ventricular assist devices in patients with severe heart failure.
    Kühne M; Sakumura M; Reich SS; Sarrazin JF; Wells D; Chalfoun N; Crawford T; Boonyapisit W; Horwood L; Chugh A; Good E; Jongnarangsin K; Bogun F; Oral H; Morady F; Pagani F; Pelosi F
    Am J Cardiol; 2010 Feb; 105(3):378-82. PubMed ID: 20102952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current implantable cardioverter-defibrillator programming in Europe: the results of the European Heart Rhythm Association survey.
    Proclemer A; Grazia Bongiorni M; Etsner H; Todd D; Sciaraffia E; Blomström-Lundqvist C;
    Europace; 2014 Jun; 16(6):935-8. PubMed ID: 24864305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baroreceptor stimulation for resistant hypertension: first implantation in France and literature review.
    Courand PY; Feugier P; Workineh S; Harbaoui B; Bricca G; Lantelme P
    Arch Cardiovasc Dis; 2014 Dec; 107(12):690-6. PubMed ID: 25445751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defibrillation testing in everyday medical practice during implantable cardioverter defibrillator implantation in France: analysis from the LEADER registry.
    Sadoul N; Defaye P; Mouton E; Bizeau O; Dupuis JM; Blangy H; Delarche N; Blanc JJ; Lazarus A;
    Arch Cardiovasc Dis; 2013 Nov; 106(11):562-9. PubMed ID: 24200925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
    Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S
    Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Battery longevity in cardiac resynchronization therapy implantable cardioverter defibrillators.
    Alam MB; Munir MB; Rattan R; Flanigan S; Adelstein E; Jain S; Saba S
    Europace; 2014 Feb; 16(2):246-51. PubMed ID: 24099864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic impact of pre-implantation hyponatremia on morbidity and mortality among patients with left ventricular dysfunction and implantable cardioverter-defibrillators.
    Bhavnani SP; Kumar A; Coleman CI; Guertin D; Yarlagadda RK; Clyne CA; Kluger J
    Europace; 2014 Jan; 16(1):47-54. PubMed ID: 23954920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world data on the lifespan of implantable cardioverter-defibrillators depending on manufacturers and the amount of ventricular pacing.
    Horlbeck FW; Mellert F; Kreuz J; Nickenig G; Schwab JO
    J Cardiovasc Electrophysiol; 2012 Dec; 23(12):1336-42. PubMed ID: 22909190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of extending device longevity on the long-term costs of implantable cardioverter-defibrillator therapy: a modelling study with a 15-year time horizon.
    Boriani G; Braunschweig F; Deharo JC; Leyva F; Lubinski A; Lazzaro C
    Europace; 2013 Oct; 15(10):1453-62. PubMed ID: 23696624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study.
    Scheffers IJ; Kroon AA; Schmidli J; Jordan J; Tordoir JJ; Mohaupt MG; Luft FC; Haller H; Menne J; Engeli S; Ceral J; Eckert S; Erglis A; Narkiewicz K; Philipp T; de Leeuw PW
    J Am Coll Cardiol; 2010 Oct; 56(15):1254-8. PubMed ID: 20883933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.